Articles tagged with Vaccination
Researchers at the NIH have successfully tested an experimental MERS vaccine in monkeys and camels, demonstrating broad protection against different strains of the virus. The vaccine uses a synthetic DNA sequence that combines elements of SARS and MERS-CoV proteins, inducing protective immunity in non-human primates.
A new synthetic DNA vaccine has been developed to induce protective immunity against the Middle East Respiratory Syndrome (MERS) coronavirus in animals. The vaccine, administered six weeks prior to exposure, was found to fully protect rhesus macaques from disease and generate potentially protective antibodies in camels.
A new study from the University of Michigan Health System found that electronic prompts and reminders resulted in significant increases in Tdap vaccine uptake among patients aged 11-64. The system improved vaccine rates by 76% for adults and 85% for adolescents, compared to 59% in similar-aged groups without automated prompts.
A single dose of the experimental Ebola virus (EBOV) vaccine VSV-EBOV has been shown to completely protect cynomolgus macaques against the current EBOV outbreak strain, EBOV-Makona. The vaccine triggers both innate and adaptive immunity, providing partial protection if given three days prior to exposure.
A preclinical study found that a new Ebola vaccine, VSV-EBOV, provides complete protection against the disease when given 7 days before infection in macaques. The vaccine also induces a strong innate immune response, helping to limit virus replication and eventually clearing the virus.
A new study from the University of Georgia found that lax state vaccination laws contribute to lower immunization rates and increased outbreaks of preventable diseases, such as whooping cough and measles. States with stricter policies have lower pertussis rates, highlighting the impact of policymakers on disease prevention.
A proposed global vaccine-development fund could help make vaccines available for emergency use, saving thousands of lives. The fund would cover the financial burden of vaccine development, addressing barriers such as high costs, limited market potential and lack of government support.
Researchers have devised a new approach to vaccines that creates immunity without standard approaches, offering a rapid solution to deadly diseases like dengue fever. The DMAb platform produces antibodies that do not bind to cell receptors, eliminating the chance for infection and disease.
Researchers at UCLA and University of Illinois found that emphasizing the benefits of vaccination and taking a non-confrontational approach can increase support for vaccination among skeptical parents. A study with 315 adults showed that highlighting the dangers of measles and mumps can substantially increase support for vaccination.
A model investigates optimal vaccination strategies to minimize cholera-related mortality and costs, considering seasonality in pathogen transmission. The study finds that effective vaccination can significantly reduce disease spread and associated expenses.
Researchers found that reminding skeptics about the importance of vaccines and the risks associated with not being vaccinated can change their attitudes positively. The study tested three groups of participants and showed that even the most skeptical individuals were influenced by the intervention.
Researchers at Georgia State University developed a vaccine containing virus-like nanoparticles that induces long-term protection against RSV. The study found that mice vaccinated with these particles showed no severe pulmonary disease and lower levels of inflammatory markers after infection.
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, producing broadly neutralizing antibodies against multiple strains of the MERS coronavirus. Vaccinated macaques were protected from severe lung damage when later exposed to MERS-CoV.
A global study found that chronic hepatitis B virus infection affects approximately 248 million people worldwide, with a disproportionately high burden in some countries. The prevalence of the disease varies significantly between countries, with up to 20% of the population infected in certain regions.
A new study published in PLOS Biology found that imperfect vaccines can promote the evolution of nastier viral strains, increasing the risk of severe illness among unvaccinated individuals. The research highlights the importance of perfect vaccines in preventing not only disease but also transmission.
Researchers are developing a cancer vaccine to combat Devil Facial Tumour Disease (DFTD), a contagious cancer killing Tasmanian devils. The vaccine aims to save the species by targeting proteins unique to the tumour cells, with hopes for eventual release into the wild.
A Phase I research study is underway to develop a vaccine that could prevent recurrence of some childhood cancers in patients who have relapsed after surgery, chemotherapy and radiation. The trial has enrolled three patients so far and aims to stimulate the immune system to attack specific tumor proteins.
The Oxford Vaccine Group is conducting a Phase II study of an Ebola vaccine regimen, recruiting over 600 healthy adult volunteers in the UK and France. The study aims to assess the safety and immunogenicity of the vaccine, as well as determine the best timing for each dose.
A collaborative team from UTMB and NIH develop an inhalable vaccine that protects primates against Ebola. The aerosol delivery method has shown promising results, with a single vaccination providing protection against the severe disease and death caused by lethal Ebola infection.
A survey of 1,500 French general physicians found that while many are confident in vaccine benefits, concerns over adjuvants and controversy surrounding certain vaccines hinder recommendations. Trust in authorities is high, but training and resources are needed to address patient hesitancy.
A new investigational vaccine designed to protect against West Nile Virus infection is being tested in a Phase 1 clinical trial. The vaccine was developed with a novel, hydrogen peroxide-based process that renders the virus inactive while maintaining key immune-system triggering surface structures.
Recent changes to EU regulations have led to an increase in imported pets from Eastern Europe, where rabies is endemic, raising concerns about the effectiveness of current checks. The study found that many stray and rescue dogs had low antibody levels against rabies, suggesting potential risks for these animals.
A new study suggests that vaccinated people who are infectious but symptom-free may be transmitting whooping cough multiple times throughout their lives, exacerbating the outbreak. The research highlights the importance of getting vaccinated, especially for children, as the primary source of protection against severe disease and death.
The institutions have selected two new research projects to receive funding through the Connecting through Research Partnerships Program. These projects aim to develop a supply chain model for biofuels and test a nasal delivery formulation of an encapsulated vaccine to prevent chlamydia.
Professor Shashi Murthy is developing a novel microfluidic system to automate the process of creating dendritic cells, essential for effective vaccines. The new instrument aims to reduce the manual process from 16 steps to a fully-automated system, potentially cutting timeframes to six days.
A team of researchers from Ludwig-Maximilians-Universität München has developed a candidate vaccine against Middle East Respiratory Syndrome (MERS) and demonstrated its efficacy in a mouse model. The vaccine, named MVA-MERS-S, uses a modified virus to induce protective immunity against the coronavirus.
A new analysis found a decline in high-grade cervical lesions among U.S. women aged 18-20 after HPV vaccination became available. However, this trend may be influenced by changes in cancer screening recommendations.
A new study using disease-transmission models shows that silent transmission of poliovirus could continue for more than three years with no reported cases. To ensure eradication, aggressive surveillance and vaccination campaigns must continue in endemic countries after the last reported case.
A new study by University of Michigan graduate research fellow Micaela Martinez-Bakker reveals that silent transmission of poliovirus could continue for more than three years with no reported cases. To ensure eradication, aggressive surveillance programs and vaccination campaigns must continue in endemic countries.
Alternative drug-delivery systems are being explored to overcome syringe injection drawbacks, including ointments, dissolvable tablets and micro-needle skin patches. Several promising results have been shown in animal testing, but widespread adoption will require changing the mindset of pharmaceutical companies and regulators.
Researchers found that regulatory T cells suppress killer T cells through a protein on their surface, enabling the immune system to remember past pathogens. This discovery could lead to faster-acting vaccines and improved immunity to diseases like cancer.
A study found that people with rheumatoid arthritis are less protected by the hepatitis B vaccine, highlighting increased risk of infection despite vaccination. The vaccine's efficacy was lower in RA patients compared to those without the condition.
A new method has identified children with rheumatic disease who are eligible for a life-saving vaccine. The vaccine was found to be safe and effective even in patients taking immunosuppression treatment.
A recent study published in The Lancet Oncology suggests that a single dose of the HPV vaccine Cervarix can provide similar protection to three doses, offering hope for improving vaccination rates. This finding is particularly relevant for states like Kentucky with low completion rates.
A study published in JAMA found that rotavirus vaccination led to a 31-55% decline in all-cause acute gastroenteritis hospitalizations and a 70-94% decline in rotavirus-coded hospitalizations among US children under 5 years old. The greatest reductions were observed among younger age groups.
Researchers at Griffith University have created a groundbreaking combination vaccine that combines the protein SpyCEP with J8-DT to combat Streptococcus A infections. The vaccine shows promise in preventing deadly complications of the infection, including rheumatic heart disease.
A randomized trial tested an intervention to improve hesitancy about early childhood vaccines, but found it had minimal effect on mothers and doctors. The intervention, called Ask, Acknowledge, and Advise, aimed to encourage respectful dialogue with parents while recommending vaccination.
A team of researchers, led by Dr. Steve Bellan and including Associate Professor Manoj Gambhir from Monash University, have identified the most effective human trial design for testing Ebola vaccines in Sierra Leone. The study suggests that a modified randomized control trial is the best approach to detect an effective and safe vaccine.
A study in The Netherlands found that vaccinating girls against HPV also protects men from some cancers. The authors suggest that authorities prioritize vaccinating as many girls as possible, but consider including boys in preadolescent vaccination programs once costs and benefits align.
The 9-Valent human papillomavirus vaccine has the potential to protect against 80% of cervical cancers and approximately 19,000 other HPV-related cancers in the US. Researchers found that 70% of oropharyngeal cancer patient DNA samples harbored HPV, likely due to changes in sexual behaviors.
A candidate vaccine has been shown to induce long-lasting immunity against the parasite that causes Chagas disease. Mice vaccinated with a combination of two parasite proteins showed reduced parasite numbers and improved immune response compared to uninfected mice.
A new study reveals that measles vaccination prevents not only measles but also other infectious diseases by damaging the immune system's memory. This finding explains why mass measles vaccinations have driven down mortality rates from other diseases in high-income countries.
Researchers at UTMB have successfully tested a vaccine for Chagas disease, which can provide long-lasting immunity in animal models. The vaccine was found to significantly reduce parasite levels and prevent chronic symptoms, making it a promising tool for control of this infection.
Researchers at Queen's University found a significant reduction in cervical dysplasia and genital warts among eligible girls who received the HPV vaccine. The study of over 260,000 girls showed that one case of cervical dysplasia was prevented for every 175 eligible girls vaccinated.
The American Academy of Pediatrics celebrates seven significant research achievements that have led to prevention and treatment strategies for diseases such as rotavirus, Haemophilus influenzae type b, SIDS, and acute lymphocytic leukemia. These advancements have saved millions of lives and improved child health worldwide.
A recent study found that a drop in vaccine protection is a likely explanation for the surge in pertussis disease cases in the US. The 'acellular' vaccine is found to have lower protection levels compared to the previously-used 'whole-cell' vaccine.
Scaling up existing interventions, including infant vaccination and treatment programmes, could prevent 90% of new chronic HBV infections and 65% mortality levels by 2030. Global expansion is necessary to achieve hepatitis B elimination, avoiding 20 million deaths by 2030.
A small artificially composed virus fragment, sAB+, has been found to be sufficient for inducing a partially protective immune response against the Chikungunya virus. This discovery presents a promising approach for developing a Chikungunya vaccine.
Researchers used TACC's Lonestar4 supercomputer to simulate and analyze data for various vaccine trial designs. They found that a phased-rollout randomized controlled trial would provide better information about the effectiveness of an Ebola vaccine.
Researchers have successfully completed the first step in developing an insulin vaccine to prevent type 1 diabetes. The Pre-POINT study showed a positive immune response in children at high risk for the disease, with no adverse reactions observed.
A large study of over 95,000 US children found no association between the MMR vaccine and an increased risk of autism spectrum disorders (ASD), even among those with older siblings already at higher genetic risk for ASD. The study suggests that parents' concerns about the vaccine's link to ASD may be unfounded.
A new study suggests that vaccinating 12-year-old boys against HPV can save $8 million to $28 million over their lifetimes due to reduced incidence of HPV-related oropharyngeal cancer. The study's findings have significant implications for public health policy in countries where HPV vaccination is not currently funded.
Researchers at UTMB have developed an Ebola vaccine that is both safe and effective with a single dose, providing protection against the deadly virus. The new vaccine employs a 'Trojan horse' approach, using a weakened form of the virus to trigger an immune response.
A phase 1 clinical trial found the VSV-EBOV Ebola vaccine to be safe and elicit a robust immune response, with 93% of volunteers developing anti-Ebola antibodies within two weeks. The vaccine's higher dose showed a stronger antibody response.
A UCLA professor of planetary astronomy confirms that the timing of human births and hospital admissions is not influenced by the lunar cycle. The study highlights the persistence of flawed beliefs despite evidence, attributed to confirmation bias, and societal costs including measles outbreaks.
Two experimental Ebola vaccines have proven safe in a phase 2 clinical trial involving over 600 participants in Liberia. The trial may now advance to Phase 3 testing if the results are confirmed, with the ultimate goal of determining whether these vaccines can protect against Ebola virus disease.
A new study reveals a cytomegalovirus-based vaccine provides protection against Ebola virus for over 14 months after a single dose, offering hope for preventing ebolavirus infection in African apes and reducing future human outbreaks. The innovative approach could help stabilize endangered ape populations and protect humans from the de...
A multivalent vaccine candidate induced broad antibody responses in trial participants, including to non-vaccine strains, suggesting a possible solution to evading immunity. The study provides evidence that VLP-based vaccines may overcome antigenic drift, but further development and clinical trials are needed for a vaccine suitable for...
The International Journal of Infectious Diseases publishes a special issue to mark World TB Day, highlighting recent successes and future challenges in eliminating TB. The issue presents new vaccine candidates, diagnostic techniques, and treatment options for drug-resistant strains.
A recent measles outbreak in California was likely caused by substandard vaccination compliance, according to a study published in JAMA Pediatrics. The study estimates that vaccination rates among exposed populations may be as low as 50 percent, highlighting the need for herd immunity.